Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Guizhou Xinbang Pharmaceutical Co Ltd
Cost of Revenue
Guizhou Xinbang Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
|
Cost of Revenue
-¥5.3B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-37%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cost of Revenue
-¥1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cost of Revenue
-¥5.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-24%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cost of Revenue
-¥3.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cost of Revenue
-¥28.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cost of Revenue
-¥242.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Guizhou Xinbang Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-5.3B
CNY
Based on the financial report for Mar 31, 2024, Guizhou Xinbang Pharmaceutical Co Ltd's Cost of Revenue amounts to -5.3B CNY.
What is Guizhou Xinbang Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-37%
Over the last year, the Cost of Revenue growth was -1%. The average annual Cost of Revenue growth rates for Guizhou Xinbang Pharmaceutical Co Ltd have been -4% over the past three years , and -37% over the past ten years .